Cabozantinib

Cabozantinib

None

Renal cell carcinoma (RCC), hepatocellular (HCC)

Sept. 22, 2021 Cabometyx (cabozantinib) has received FDA approval for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior vascular endothelial growth factor receptor-targeted therapy and who are radioactive iodine-refractory or ineligible

January 22, 2021 FDA approved the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx), as first-line treatment for patients with advanced renal cell carcinoma (RCC).

Received approval under the FDA priority review program November 29, 2012 for treatment of medullary cancer of the thyroid.

April 25, 2016: The FDA approved cabozantinib for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.

1/14/2019 FDA approved Cabometyx (cabozantinib) tablets for patients with hepatocellular carcinoma who have been previously treated with sorafenib

This drug should be coded